Buy Bromo-DragonFLY for sale online from USA vendor
Table of Contents
- Introduction
- Chemistry
- Pharmacology
- Effects
- Subjective Effects
- Physical Effects
- Visual Effects
- Hallucinatory States
- Cognitive Effects
- Toxicity and Harm Potential
- Subjective Effects
- Legal Status
- Frequently Asked Questions (FAQ)
Introduction
Bromo-DragonFLY, also known as DOB-DragonFLY or simply B-DFLY or Dragonfly, stands out as a novel psychedelic substance belonging to the amphetamine and benzodifuran classes. Its synthesis dates back to 1998 when Matthew Parker first created it from DOB-FLY, although the specific citation for this information remains elusive.
Potency and Effects
This compound boasts extraordinary potency, eliciting a wide range of intensely dose-sensitive psychedelic effects upon administration. Remarkably, its effects can endure for unusually extended periods, potentially spanning several days. Relative to other psychedelics, Bromo-DragonFLY is believed to possess approximately one-third the potency of LSD by weight, making it an exceptionally potent substance within the realm of psychedelic compounds.
Safety Considerations
Despite its allure, Bromo-DragonFLY poses significant challenges regarding safe usage. Reports suggest that its high potency and unpredictable dose-response profile render it particularly challenging for individuals lacking prior experience with hallucinogens. As dosage and duration remain insufficiently determined, caution is paramount. It is strongly recommended that users commence with the lowest feasible dosage, restrict intake solely to oral routes of administration, and refrain from redosing at any point during the experience.
Pharmacology and Safety Profile
The pharmacological, metabolic, and toxicological characteristics of Bromo-DragonFLY in humans remain shrouded in mystery. Its brief surge in popularity among research chemicals around 2010 was abruptly halted by a series of fatalities stemming from mislabeling incidents. Notably, Bromo-DragonFLY was mistakenly sold as 2C-B-FLY, prompting its subsequent prohibition.
Current Status and Recommendations
Despite its initial emergence, Bromo-DragonFLY has never been reported as being sold on the street and appears to have ceased production within the research chemicals gray market. Given its novelty and limited history of human consumption, all information pertaining to its use should be approached with extreme caution. Individuals opting to experiment with this substance are strongly urged to employ stringent harm reduction practices to mitigate potential risks.
Understanding Bromo-DragonFLY Dosage
Dosage Ranges
Bromo-DragonFLY, a potent psychedelic substance, exhibits a dose-response relationship that warrants careful consideration. Below are the dosage thresholds and their corresponding effects:
Threshold Dosage: 75 µg
At this level, users may begin to perceive subtle effects characteristic of Bromo-DragonFLY's psychedelic properties.
Light Dosage: 100 - 300 µg
Within this range, users typically experience mild to moderate psychedelic effects, often characterized by alterations in perception and mood.
Common Dosage: 300 - 500 µg
Falling within this bracket, users can anticipate more pronounced psychedelic effects, with heightened sensory experiences and perceptual distortions.
Strong Dosage: 500 - 750 µg
In this range, the psychedelic effects become notably intense, potentially leading to profound alterations in consciousness and perception.
Heavy Dosage: 750 µg and above
At doses surpassing 750 µg, users may encounter overwhelmingly potent psychedelic effects, which can include profound distortions of reality and intense introspective experiences. Extreme caution is advised at this level due to the heightened risk of adverse reactions and psychological distress.
Unraveling Bromo-DragonFLY: Chemistry, Pharmacology, and Effects
Chemistry
Bromo-DragonFLY is a complex compound, belonging to the substituted phenethylamine, amphetamine, and benzofuran classes. Its molecular structure consists of a phenyl ring bound to an amino (NH2) group via an ethyl chain, with a bromine atom attached to carbon R4. Structurally, it closely resembles DOB, functioning as the difuran analog to DOB. This distinction is characterized by the incorporation of methoxy groups bound to R2 and R5 of DOB into five-membered furan rings fused to the central benzene ring. Notably, the R-isomer of Bromo-DragonFLY demonstrates considerably higher activity compared to its counterpart, necessitating dosage adjustments.
Phenethylamine Derivatives: The DragonFLY Compounds
Bromo-DragonFLY is part of a group of phenethylamine derivatives known as the DragonFLY compounds, named for their insect-like appearance with two "wing-like" furan rings fused on opposite sides of the central benzene ring.
Pharmacology
Bromo-DragonFLY exerts its hallucinogenic effects primarily through agonist activity at the 5-HT2A serotonin receptor. Additionally, it exhibits high binding affinity for the 5-HT2B and 5-HT2C serotonin receptors. Despite being non-subtype selective, Bromo-DragonFLY demonstrates greater potency as an agonist for 5-HT2C receptors compared to 5-HT2A receptors. It also appears to inhibit MAO-A activity significantly, contributing to its prolonged duration of action. However, the precise mechanisms underlying its psychedelic experience remain elusive.
Effects
Compared to LSD, Bromo-DragonFLY induces less pronounced body highs and visual effects, instead offering more profound hallucinations akin to mescaline or 2C-B. Despite these effects, users often maintain cognitive clarity, experiencing diminished confusion and potential delusions compared to other psychedelics like 4-AcO-DMT, psilocin, or LSD.
Subjective Effects
Physical Effects
- Stimulation & Sedation: At lower doses, Bromo-DragonFLY provides gentle stimulation similar to 2C-B or mescaline, but higher doses may lead to uncomfortable levels of stimulation or significant sedation.
- Spontaneous Bodily Sensations: Users may experience a pleasurable, warm, tingling sensation comparable to milder mescaline or 2C-B experiences.
- Other physical effects include muscle contractions, dehydration, pupil dilation, and vasoconstriction.
Visual Effects
- Enhancements: Bromo-DragonFLY enhances color perception, visual acuity, and pattern recognition.
- Distortions: Users may experience drifting, color shifting, and perspective distortions reminiscent of 2C-B or mescaline.
Hallucinatory States
Bromo-DragonFLY induces a broad spectrum of hallucinatory states, akin to mescaline or 2C-E, integrating seamlessly with accompanying visual geometry.
Cognitive Effects
- Analysis Enhancement
- Creativity Enhancement
- Emotion Enhancement
- Memory Suppression
- Ego Death
- Increased Music Appreciation
- Immersion Enhancement
Toxicity and Harm Potential
Bromo-DragonFLY poses significant toxicity risks, with reported deaths and hospitalizations at high doses. Its extreme vasoconstrictive effects can lead to severe tissue damage or limb amputation. Due to its potency and limited human usage history, accurate dosing and harm reduction practices are crucial.
Legal Status
Bromo-DragonFLY is subject to varying legal statuses worldwide, with many countries prohibiting its production, sale, and possession. Notably, it is listed as a Schedule I substance in the United States and is illegal in the United Kingdom under the Psychoactive Substance Act.
Frequently Asked Questions (FAQ)
1. What is Bromo-DragonFLY?
Bromo-DragonFLY is a potent psychedelic substance belonging to the amphetamine and benzofuran classes. It is known for its long-lasting effects and high potency.
2. How does Bromo-DragonFLY compare to other psychedelics?
Compared to substances like LSD, Bromo-DragonFLY induces less pronounced body highs and visual effects but offers more profound hallucinations akin to mescaline or 2C-B. Users often maintain cognitive clarity despite experiencing intense psychedelic effects.
3. What are the physical effects of Bromo-DragonFLY?
Bromo-DragonFLY can produce various physical effects, including stimulation or sedation, spontaneous bodily sensations, muscle contractions, dehydration, pupil dilation, and vasoconstriction.
4. What are the legal implications of Bromo-DragonFLY?
Bromo-DragonFLY is subject to varying legal statuses worldwide, with many countries prohibiting its production, sale, and possession. In the United States, it is classified as a Schedule I substance, and in the United Kingdom, it is illegal under the Psychoactive Substance Act.
5. Is Bromo-DragonFLY safe to use?
Bromo-DragonFLY poses significant toxicity risks, with reported deaths and hospitalizations at high doses. Due to its potency and limited human usage history, accurate dosing and harm reduction practices are crucial.
6. How does Bromo-DragonFLY affect cognitive function?
Bromo-DragonFLY can enhance analysis, creativity, emotion, memory suppression, ego death, music appreciation, immersion, and induce time distortion and wakefulness.
7. What precautions should be taken when using Bromo-DragonFLY?
Users should exercise extreme caution and adhere to harm reduction practices when using Bromo-DragonFLY. This includes accurate dosing, avoiding re-dosing, and being aware of potential adverse effects such as vasoconstriction and tissue damage.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics